SAN
DIEGO, Feb. 27, 2024 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that
Dr. Helen Torley, president and
chief executive officer, is scheduled to present and host investor
meetings at the following investor conferences:
Event:
|
TD Cowen
44th Annual Healthcare Conference
|
Format:
|
Fireside Chat and 1x1
Meetings
|
Presentation
Date:
|
Tuesday, March 5,
2024
|
Presentation Time:
|
11:50 a.m. PT / 2:50
p.m. ET
|
Location:
|
Boston, MA
|
|
|
Event:
|
Leerink Partners Global
Biopharma Conference 2024
|
Format:
|
Fireside Chat and 1x1
Meetings
|
Presentation
Date:
|
Tuesday, March 12,
2024
|
Presentation
Time:
|
12:00 p.m. PT / 3:00
p.m. ET
|
Location:
|
Miami, FL
|
|
|
Event:
|
Barclays
26th Annual Global Healthcare Conference
|
Format:
|
Fireside Chat and 1x1
Meetings
|
Presentation Date:
|
Wednesday, March 13,
2024
|
Presentation Time:
|
7:45 a.m. PT / 10:45
a.m. ET
|
Location:
|
Miami, FL
|
Live audio webcasts of the presentations will be available on
the Investor Relations section of the Company's website.
Replays of the audio webcasts will be available for 90 days
following the conference.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive
solutions to improve patient experiences and outcomes for emerging
and established therapies. As the innovators of ENHANZE®
drug delivery technology with the proprietary enzyme rHuPH20,
Halozyme's commercially-validated solution is used to facilitate
the subcutaneous delivery of injected drugs and fluids, with the
goal of reducing treatment burden for patients. Having touched more
than 800,000 patient lives in post-marketing use in seven
commercialized products across more than 100 global markets,
Halozyme has licensed its ENHANZE® technology to leading
pharmaceutical and biotechnology companies including Roche, Takeda,
Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx,
ViiV Healthcare, Chugai Pharmaceutical and Acumen
Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for
itself or with partners, drug-device combination products using its
advanced auto-injector technologies that are designed to provide
commercial or functional advantages such as improved convenience,
reliability and tolerability, and enhanced patient comfort and
adherence. The Company has two commercial proprietary products,
Hylenex® and XYOSTED®, partnered commercial
products and ongoing product development programs with several
pharmaceutical companies including Teva Pharmaceuticals and Idorsia
Pharmaceuticals.
Halozyme is headquartered in San
Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations
facility.
For more information visit www.halozyme.com and connect
with us on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Samantha Gaspar
Teneo
617-877-9710
samantha.gaspar@teneo.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-to-participate-in-upcoming-investor-conferences-302072329.html
SOURCE Halozyme Therapeutics, Inc.